^
    1d
    ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab (clinicaltrials.gov)
    P4, N=90, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • IFNA1 (Interferon Alpha 1)
    |
    Signatera™
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1d
    ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P1/2, N=41, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1/2 trial
    |
    Meiyouheng (becotatug vedotin) • Qibeian (iparomlimab/tuvonralimab)
    1d
    Durvalumab and Tremelimumab for Pediatric Malignancies (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)
    2d
    Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Feb 2026 --> Feb 2027 | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)
    3d
    Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) (2024-513219-29-00)
    P2/3, N=203, Recruiting, University College London | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    3d
    Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial. (PubMed, Gynecol Oncol)
    Cadonilimab combined with chemotherapy demonstrated clinically meaningful activity and manageable safety as first-line treatment for advanced or recurrent EC, supporting further investigation, particularly in molecularly defined populations.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Kaitanni (cadonilimab)
    5d
    Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report. (PubMed, Front Oncol)
    Two cycles of nivolumab plus ipilimumab were performed before discovering severe cervical spine pain. Here we show (1) robust CD3+ and CD20+ infiltration in primary tumors and metastases, with immune cells in direct contact with tumor cells or organized in lymphoid aggregates/tertiary lymphoid structures; (2) PD-L1 overexpression in sRCC and nodal metastasis but absent in post-immunotherapy bone lesions; (3) increased CD163+ macrophages in sRCC and metastases versus ccRCC. This case illustrates that ICIs can induce near-complete eradication of bone metastases; that bone is not an immune-exempt organ, with massive intratumoral immune cell infiltration; and that immediate immune-mediated tumor clearance prevents structural skeletal damage, which merits careful surveillance.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD163 (CD163 Molecule) • CA9 (Carbonic anhydrase 9) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    5d
    Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov)
    P2, N=47, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide
    5d
    LORIKEET: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=154, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    docetaxel • prednisone • lorigerlimab (MGD019)
    6d
    Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    6d
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (clinicaltrials.gov)
    P2/3, N=680, Recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin • Tabosun (ipilimumab N01 injection)